文献速递心血管技术与安全PETCTMR

浆细胞治疗后心肌轻链淀粉样蛋白负荷的变化

Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-09-12

这项前瞻性研究纳入81例新诊断、活检证实的AL淀粉样变性患者,在基线、6个月和/或12个月行18F-florbetapir PET/CT和心脏磁共振检查。结果显示,在AL淀粉样心肌病中,治疗6个月和12个月时淀粉样蛋白负荷(%ID)显著下降,且该变化与NT-proBNP反应相关;而ECV在生物标志物反应者中未见变化。

要点

  • 在AL淀粉样心肌病中,18F-florbetapir %ID在治疗后6个月和12个月均显著下降。
  • %ID变化与NT-proBNP变化在12个月时呈中度相关(ρ=0.531)。
  • 生物标志物反应者%ID显著下降(P<0.001),非反应者无变化(P=0.542)。

核心结论

  • 18F-florbetapir %ID估计的心肌AL淀粉样蛋白负荷在浆细胞治疗患者中下降,且6个月即可检测到;分子淀粉样蛋白与ECV变化可能反映AL淀粉样变性心肌重构的不同方面。

研究设计与样本

  • 前瞻性研究纳入81例新诊断、活检证实的AL淀粉样变性患者(58例AL淀粉样心肌病,23例无心肌病的AL淀粉样变性),在基线、6个月(n=52)和/或12个月(n=37)行18F-florbetapir PET/CT和心脏磁共振(包括ECV)检查。

诊断标准与关键数值

  • 分子淀粉样蛋白负荷以18F-florbetapir注射剂量百分比(%ID)估计,变化以绝对和相对%ID变化表示。
  • 心脏生物标志物反应定义为基线NT-proBNP≥650 ng/L时,NT-proBNP降低>30%且>300 ng/L。
  • 在AL淀粉样心肌病中,%ID中位绝对变化为-0.3%(相对变化-13%),6个月时P=0.002;12个月时中位绝对变化-0.3%(相对变化15%),P=0.003。

临床应用与阅片要点

  • 作者认为,18F-florbetapir %ID可在浆细胞治疗后6个月检测到心肌AL淀粉样蛋白负荷下降。
  • 作者认为,分子淀粉样蛋白与ECV变化可能反映AL淀粉样变性心肌重构的不同方面。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Current therapies for light chain (AL) amyloidosis target the plasma cell dyscrasia, but their effect on myocardial amyloid fibril burden remains poorly defined.

OBJECTIVES: The authors aimed to assess longitudinal changes in myocardial amyloid burden after plasma cell-directed chemotherapy.

METHODS: This prospective study included 81 patients (58 with AL amyloid cardiomyopathy and 23 with AL amyloidosis without cardiomyopathy) with recently diagnosed, biopsy-proven AL amyloidosis, who underwent serial 18F-florbetapir positron emission tomography/computed tomography and cardiac magnetic resonance (including extracellular volume [ECV]) at baseline, 6 months (n = 52), and/or 12 months (n = 37). Molecular amyloid burden was estimated as 18F-florbetapir percentage injected dose (%ID), and changes are presented as absolute and relative %ID changes. Cardiac biomarker response was defined as a reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) >30% and >300 ng/L when baseline NT-proBNP ≥650 ng/L. All change comparisons were paired within patients.

RESULTS: In AL amyloid cardiomyopathy, amyloid burden decreased significantly at 6 and 12 months after therapy initiation (median absolute [relative] change %ID: -0.3% [-13%]; P = 0.002; and -0.3% [15%]; P = 0.003). Changes in %ID correlated moderately with changes in NT-proBNP at 12 months (ρ = 0.531). Of note, %ID decreased significantly among biomarker responders (P < 0.001), whereas there was no change in nonresponders (P = 0.542). In contrast, ECV did not change in biomarker responders (P = 0.193) or nonresponders (P = 0.695). In AL amyloidosis without cardiomyopathy, %ID did not change (P = 0.523), whereas ECV increased (P = 0.011).

CONCLUSIONS: Myocardial AL amyloid burden estimated by 18F-florbetapir %ID decreases in participants undergoing plasma cell therapy and is detectable at 6 months. Molecular amyloid and ECV changes probably reflect distinct aspects of myocardial remodeling in AL amyloidosis. (Molecular Imaging of Primary Amyloid Cardiomyopathy [MICA]: NCT02641145).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Benz DC, Clerc OF, Cuddy SAM, et al. Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy. JACC Cardiovasc Imaging. 2025. PMID: 40938234. doi:10.1016/j.jcmg.2025.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。